 |
인쇄하기
취소
|
Competition to be seen intensifying in hepatitis B drugs
Multination pharmaceutical companies, such as GlaxoSmithKline (GSK), BMS and Novartis, are stepping up their maketing in domestic hepatitis B treatment drug market valued at 100 billion won, which is forecast to become more competitive ever this year.
Meanwhile, a total of 34 local drug makers obtained the marketing authorization of Hepsera (adefovir dipivoxil) generics on April 30, accordin...
Meanwhile, a total of 34 local drug makers obtained the marketing authorization of Hepsera (adefovir dipivoxil) generics on April 30, accordin...
Fees
- Email service daily and homepage access.
- $300 per month.
- 5 Email holders per each company.
- Anual contract base.
Copyright Yakup.com All rights reserved.
약업닷컴의 모든 컨텐츠는 저작권법의 보호를 받습니다. 무단 전재⋅복사⋅배포 등을 금합니다.
약업닷컴의 모든 컨텐츠는 저작권법의 보호를 받습니다. 무단 전재⋅복사⋅배포 등을 금합니다.